BTIM Boatim Inc (CE)

BioTime, Inc. (OTCBB:BTIM) announced today that Dr. David Jin, Chief Medical Officer of BioTime’s subsidiary OncoCyte Corporation, will present the keynote address at the Fifth Chinese Congress on Stem Cell Therapy in Beijing, Peoples Republic of China.

The presentation titled, “Chemokine regulation of hematopoietic stem cell mobilization and angiogenesis” will be delivered on Friday, October 23, 2009 on behalf of OncoCyte Corporation and BioTime Asia. The presentation will address the novel therapeutic strategy of using hemangiogenic stem cell technology to target and destroy tumors. This Congress is one of the largest of its type in China with over 2,000 participants from various stem cell-related disciplines.

About BioTime, Inc.

BioTime, headquartered in Alameda, California, is a biotechnology company focused on regenerative medicine and blood plasma volume expanders. BioTime develops and markets research products in the field of stem cells and regenerative medicine through its wholly owned subsidiary Embryome Sciences, Inc. BioTime’s subsidiary OncoCyte Corporation focuses on the therapeutic applications of stem cell technology in cancer. BioTime also plans to develop therapeutic products in China for the treatment of ophthalmologic, skin, musculo-skeletal system and hematologic diseases, including the targeting of genetically modified stem cells to tumors as a novel means of treating currently incurable forms of cancer through its subsidiary BioTime Asia. In addition to its stem cell products, BioTime markets blood plasma volume expanders and related technology for use in surgery, emergency trauma treatment, and other applications. BioTime's lead product, Hextend®, is a blood plasma volume expander manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corp. under exclusive licensing agreements. Additional information about BioTime can be found on the web at www.biotimeinc.com.

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for the company and its subsidiary, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list: http://www.b2i.us/irpass.asp?BzID=1152&to=ea&s=0

Boatim (CE) (USOTC:BTIM)
過去 株価チャート
から 11 2024 まで 12 2024

Boatim (CE) (USOTC:BTIM)
過去 株価チャート
から 12 2023 まで 12 2024